## Francisco-José VÃ;zquez-Polo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2697533/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of home respiratory polygraphy for the diagnosis of sleep apnoea and hypopnoea syndrome. Thorax, 2011, 66, 567-573.	5.6	139
2	Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet, The, 2019, 393, 1721-1732.	13.7	126
3	A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: a multicentre randomised controlled trial. Thorax, 2015, 70, 1054-1061.	5.6	103
4	Role of primary care in the follow-up of patients with obstructive sleep apnoea undergoing CPAP treatment: a randomised controlled trial. Thorax, 2015, 70, 346-352.	5.6	54
5	Comprehensive management of obstructive sleep apnea by telemedicine: Clinical improvement and cost-effectiveness of a Virtual Sleep Unit. A randomized controlled trial. PLoS ONE, 2019, 14, e0224069.	2.5	38
6	Effectiveness of sequential automatic-manual home respiratory polygraphy scoring. European Respiratory Journal, 2013, 41, 879-887.	6.7	35
7	Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 586-597.	5.6	34
8	A new skew generalization of the normal distribution: Properties and applications. Computational Statistics and Data Analysis, 2010, 54, 2021-2034.	1.2	33
9	Bayesian meta-analysis: The role of the between-sample heterogeneity. Statistical Methods in Medical Research, 2018, 27, 3643-3657.	1.5	31
10	Effectiveness of Three Sleep Apnea Management Alternatives. Sleep, 2013, 36, 1799-1807.	1.1	29
11	Long-term Noninvasive Ventilation in Obesity Hypoventilation Syndrome Without Severe OSA. Chest, 2020, 158, 1176-1186.	0.8	23
12	Measuring sensitivity in a bonus–malus system. Insurance: Mathematics and Economics, 2002, 31, 105-113.	1.2	21
13	Bayesian Analysis of Interval Data Contingent Valuation Models and Pricing Policies. Journal of Business and Economic Statistics, 2004, 22, 431-442.	2.9	21
14	An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. Journal of Mental Health Policy and Economics, 2005, 8, 153-65.	0.6	20
15	Elicitation of Expert Opinion in Benefit Transfer of Environmental Goods. Environmental and Resource Economics, 2003, 26, 199-210.	3.2	19
16	Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach. Journal of Health Economics, 2008, 27, 1250-1259.	2.7	18
17	Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea. Thorax, 2020, 75, 459-467.	5.6	18
18	The Esscher premium principle in risk theory: a Bayesian sensitivity study. Insurance: Mathematics and Economics, 1999, 25, 387-395.	1.2	17

#	Article	IF	CITATIONS
19	A Bayesian model for benefit transfer: application to national parks in Spain. Applied Economics, 2002, 34, 749-757.	2.2	17
20	Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane. Health Economics (United Kingdom), 2006, 15, 363-372.	1.7	17
21	On the Use of Conditional Specification Models in Claim Count Distributions: an Application to Bonus-Malus Systems. ASTIN Bulletin, 2004, 34, 85-98.	1.0	16
22	On the use of posterior regret -minimax actions to obtain credibility premiums. Insurance: Mathematics and Economics, 2006, 39, 115-121.	1.2	16
23	Using covariates to reduce uncertainty in the economic evaluation of clinical trial data. Health Economics (United Kingdom), 2005, 14, 545-557.	1.7	15
24	Objective Bayesian metaâ€analysis for sparse discrete data. Statistics in Medicine, 2014, 33, 3676-3692.	1.6	15
25	Optimal healthcare decisions: Comparing medical treatments on a cost-effectiveness basis. European Journal of Operational Research, 2010, 204, 180-187.	5.7	13
26	Bayesian regression models for cost-effectiveness analysis. European Journal of Health Economics, 2005, 6, 45-52.	2.8	12
27	Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis. European Journal of Operational Research, 2012, 218, 512-522.	5.7	12
28	A Class of Conjugate Priors for Log-Normal Claims Based on Conditional Specification. Journal of Risk and Insurance, 2005, 72, 479-495.	1.6	10
29	Bounds for Ratios of Posterior Expectations: Applications in the Collective Risk Model. Scandinavian Actuarial Journal, 2002, 2002, 37-44.	1.7	8
30	Using a Bayesian Structural Time–Series Model to Infer the Causal Impact on Cigarette Sales of Partial and Total Bans on Public Smoking. Jahrbucher Fur Nationalokonomie Und Statistik, 2018, 238, 423-439.	0.7	7
31	A discrete version of the half-normal distribution and its generalization with applications. Statistical Papers, 2014, 55, 497-511.	1.2	6
32	Effectiveness of CPAP vs. Noninvasive Ventilation Based on Disease Severity in Obesity Hypoventilation Syndrome and Concomitant Severe Obstructive Sleep Apnea. Archivos De Bronconeumologia, 2022, 58, 228-236.	0.8	5
33	A Bayesian Approach to Double Bounded Contingent Valuation. Environmental and Resource Economics, 1998, 11, 197-215.	3.2	4
34	Self-perceived health status of schizophrenic patients in Spain: analysis of geographic differences. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 531-540.	1.4	4
35	Complementing the net benefit approach: A new framework for Bayesian cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 2009, 25, 537-545.	0.5	4
36	Complementing information from incremental net benefit: a Bayesian perspective. Health Services and Outcomes Research Methodology, 2010, 10, 86-99.	1.8	4

#	Article	IF	CITATIONS
37	Complementary information for skewness measures. Statistica Neerlandica, 2015, 69, 442-459.	1.6	4
38	A Bayesian sensitivity study of risk difference in the meta-analysis of binary outcomes from sparse data. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 317-322.	1.4	4
39	A Marshall–Olkin family of heavy-tailed distributions which includes the lognormal one. Communications in Statistics - Theory and Methods, 2016, 45, 2023-2044.	1.0	4
40	Bayesian Meta-Analysis for Binary Data and Prior Distribution on Models. International Journal of Environmental Research and Public Health, 2021, 18, 809.	2.6	4
41	Modelling uncertainty in insurance Bonus–Malus premium principles by using a Bayesian robustness approach. Journal of Applied Statistics, 2005, 32, 771-784.	1.3	3
42	A note on computing bonus-malus insurance premiums using a hierarchical bayesian framework. Test, 2006, 15, 345-359.	1.1	3
43	Using a Bayesian Hierarchical Model for Fitting Automobile Claim Frequency Data. Communications in Statistics - Theory and Methods, 2008, 37, 1425-1435.	1.0	3
44	A Bayesian Net Benefit Approach to Costâ€effectiveness Analysis in Health Technology Assessment. International Journal of the Economics of Business, 2009, 16, 323-345.	1.7	3
45	On the independence between risk profiles in the compound collective risk actuarial model. Mathematics and Computers in Simulation, 2012, 82, 1419-1431.	4.4	3
46	Optimal treatments in cost-effectiveness analysis in the presence of covariates: Improving patient subgroup definition. European Journal of Operational Research, 2013, 226, 173-182.	5.7	3
47	A Note on Ordering Probability Distributions by Skewness. Symmetry, 2018, 10, 286.	2.2	3
48	Generalising Exponential Distributions Using an Extended Marshall–Olkin Procedure. Symmetry, 2020, 12, 464.	2.2	3
49	A note on the Quasi-Bayesian audit risk model for dollar unit sampling1. European Accounting Review, 1997, 6, 501-507.	3.8	2
50	Analysing the independence hypothesis in models for rare errors: an application to auditing. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 795-804.	1.0	2
51	Bayesian Variable Selection in Cost-Effectiveness Analysis. International Journal of Environmental Research and Public Health, 2010, 7, 1577-1596.	2.6	2
52	Comparing meta-analyses for chronic obstructive pulmonary disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 277-279.	1.4	2
53	Meta-Analysis with Few Studies and Binary Data: A Bayesian Model Averaging Approach. Mathematics, 2020, 8, 2159.	2.2	2
54	Robust Bayesian bonus-malus premiums under the conditional specification model. Statistical Papers, 2009. 50. 465-480.	1.2	1

## FRANCISCO-JOSé VÃizQUEZ-PO

#	Article	IF	CITATIONS
55	Cost-effectiveness analysis for heterogeneous samples. European Journal of Operational Research, 2016, 254, 127-137.	5.7	1
56	Bayesian Inference in Auditing With Partial Prior Information Using Maximum Entropy Priors. Entropy, 2018, 20, 919.	2.2	1
57	Exact credibility reference Bayesian premiums. Insurance: Mathematics and Economics, 2022, 105, 128-143.	1.2	1
58	Behaviour of the posterior error rate with partial prior information in auditing. Journal of Applied Statistics, 1995, 22, 469-476.	1.3	0
59	"Principal Applications of Bayesian Methods in Actuarial Science: A Perspectiveâ€, Udi E. Makov, October 2001. North American Actuarial Journal, 2001, 5, 62-67.	1.4	Ο
60	An application of the Morgenstern family with standard twoâ€sided power and gamma marginal distributions to the Bayes premium in the collective risk model. Applied Stochastic Models in Business and Industry, 2013, 29, 468-478.	1.5	0
61	Objective Bayesian model choice for non-nested families: the case of the Poisson and the negative binomial. Test, 2021, 30, 255-273.	1.1	0
62	Bayesian Approach to Evidence Synthesis. , 2016, , 155-160.		0
63	Contagious statistical distributions: k-connections and applications in infectious disease environments. PLoS ONE, 2022, 17, e0268810.	2.5	0
64	Bayesian heterogeneity in a meta–analysis with two studies and binary data. Journal of Applied Statistics, 0, , 1-17.	1.3	0